ATE381344T1 - Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a - Google Patents

Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a

Info

Publication number
ATE381344T1
ATE381344T1 AT00944677T AT00944677T ATE381344T1 AT E381344 T1 ATE381344 T1 AT E381344T1 AT 00944677 T AT00944677 T AT 00944677T AT 00944677 T AT00944677 T AT 00944677T AT E381344 T1 ATE381344 T1 AT E381344T1
Authority
AT
Austria
Prior art keywords
surfactant
lipid
derivative
attenuated
monophosphoryl lipid
Prior art date
Application number
AT00944677T
Other languages
German (de)
English (en)
Inventor
R Crane
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE381344T1 publication Critical patent/ATE381344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00944677T 1999-06-22 2000-06-14 Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a ATE381344T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/338,182 US6491919B2 (en) 1997-04-01 1999-06-22 Aqueous immunologic adjuvant compostions of monophosphoryl lipid A

Publications (1)

Publication Number Publication Date
ATE381344T1 true ATE381344T1 (de) 2008-01-15

Family

ID=23323749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00944677T ATE381344T1 (de) 1999-06-22 2000-06-14 Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a

Country Status (9)

Country Link
US (1) US6491919B2 (https=)
EP (1) EP1194166B1 (https=)
JP (1) JP2003502388A (https=)
AT (1) ATE381344T1 (https=)
AU (1) AU775942B2 (https=)
CA (1) CA2376829A1 (https=)
DE (1) DE60037514T2 (https=)
ES (1) ES2296629T3 (https=)
WO (1) WO2000078353A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
EP2000144A1 (en) * 2000-05-19 2008-12-10 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US7848801B2 (en) 2005-12-30 2010-12-07 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
AU2009248810B2 (en) * 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
BRPI1014031A2 (pt) * 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CA2841356C (en) 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
WO2013038185A1 (en) 2011-09-12 2013-03-21 Jonathan Norden Weber Methods and compositions for raising an immune response to hiv
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
EP3069729A1 (en) 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
IL308201A (en) 2020-09-17 2024-01-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산
WO2022251455A1 (en) * 2021-05-27 2022-12-01 Revelation Biosciences, Inc. Methods of treating or preventing allergies and chronic nasal congestion
WO2025058011A1 (ja) * 2023-09-13 2025-03-20 国立大学法人大阪大学 経鼻投与用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
ATE372783T1 (de) * 1993-01-22 2007-09-15 Sloan Kettering Inst Cancer Gangliosid-klh-konjugatimpfstoffe mit qs-21 zur verzögerung des wiederauftretens eines melanoms
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法

Also Published As

Publication number Publication date
AU775942B2 (en) 2004-08-19
DE60037514D1 (de) 2008-01-31
CA2376829A1 (en) 2000-12-28
JP2003502388A (ja) 2003-01-21
WO2000078353A2 (en) 2000-12-28
ES2296629T3 (es) 2008-05-01
US6491919B2 (en) 2002-12-10
EP1194166B1 (en) 2007-12-19
AU5873800A (en) 2001-01-09
DE60037514T2 (de) 2008-12-24
WO2000078353A3 (en) 2001-03-15
US20020009456A1 (en) 2002-01-24
EP1194166A2 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
ATE381344T1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
ATE278419T1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
CA2205022C (fr) Adjuvant pour composition vaccinale
US20020041861A1 (en) Novel polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
EP0944397B1 (en) Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances
JPH09508349A (ja) 安定化オルトケイ酸含有調製物および生物学的調製物
DE69313865D1 (de) Geschmacksmaskierende zusammensetzungen von ranitidin
US8481043B2 (en) Nasal immunization
Blom et al. Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition
FR2533827A1 (fr) Composition possedant des proprietes immunoregulatrices, notamment d'adjuvants immunologiques non specifiques, a base de muramylpeptide et d'un derive d'aluminium
ATE192735T1 (de) Verfahren zur herstellung von aminoxyd tenside enthaltenden festen zusammensetzungen
CA1259750A (fr) Derives lipophiles de muramylpeptides ayant des proprietes d'activation des macrophages, compositions les contenant et procede pour les obtenir
BE1024228B1 (fr) Nouvelles formulations d'adjuvants
US20080226709A1 (en) Phospholipid membrane preparation
US20020031543A1 (en) Adjuvant comprising pulmonary surfactant
JP2887733B2 (ja) アジュバント剤
EP1267937B1 (de) Polysaccharid-polypeptid konjugat
EP1183044B1 (en) Adjuvant combinations for immunization and vaccines
KR0178422B1 (ko) 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
EP0748214B1 (fr) Liposomes, et leur utilisation notamment pour l'obtention de compositions immunomodulatrices
KR0173366B1 (ko) B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
KR100189701B1 (ko) B형 간염 바이러스의 x 단밸직 유래의 펩타이드 항원을 함유하는 리포좀
KR0173365B1 (ko) C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
JP2026504779A (ja) ワクチンアジュバントとして有用な化合物および製剤
CO4180620A1 (es) Proceso para preparar formulaciones solidas que contienen tensioactivos de oxido de amina, que comprende una sal so- luble en agua de acido maleico-oxido de amina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties